Henlius Secures NMPA IND for HLX319 Breast Cancer Drug
SHANGHAI, China, April 1, 2026 Shanghai Henlius Biotech, Inc. announced that the China National Medical Products Administration (NMPA) has...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SHANGHAI, China, April 1, 2026 Shanghai Henlius Biotech, Inc. announced that the China National Medical Products Administration (NMPA) has...
NEW YORK, NEW YORK, UNITED STATES — February 17, 2026 OS Therapies has announced a major global regulatory update...
